DAE HWA Pharmaceutical Co. Ltd (067080) — Capital Reinvestment Ratio
DAE HWA Pharmaceutical Co. Ltd (067080) has a Capital Reinvestment Ratio of 0.80x as of December 2025, meaning it reinvests 1% of its operating cash flow (₩2.06 Billion) in capital expenditures (₩1.65 Billion). See net asset quality index of DAE HWA Pharmaceutical Co. Ltd to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
DAE HWA Pharmaceutical Co. Ltd Capital Reinvestment Ratio (2011–2025)
This chart tracks DAE HWA Pharmaceutical Co. Ltd's Capital Reinvestment Ratio across 13 annual periods. Check total reinvestment intensity of DAE HWA Pharmaceutical Co. Ltd to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for DAE HWA Pharmaceutical Co. Ltd (2011–2025)
Year-by-year Capital Reinvestment Ratio for DAE HWA Pharmaceutical Co. Ltd from 2011 to 2025. For live market cap and broader valuation context, see DAE HWA Pharmaceutical Co. Ltd (067080) total market value.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.87x | ₩5.43 Billion | ₩4.73 Billion | ▼ -13.2% |
| 2024 | 1.00x | ₩6.13 Billion | ₩6.14 Billion | ▼ -74.7% |
| 2022 | 3.97x | ₩8.05 Billion | ₩31.94 Billion | ▲ +188.1% |
| 2021 | 1.38x | ₩10.45 Billion | ₩14.40 Billion | ▼ -61.5% |
| 2020 | 3.58x | ₩2.90 Billion | ₩10.38 Billion | ▲ +680.2% |
| 2018 | 0.46x | ₩10.49 Billion | ₩4.81 Billion | ▼ -30.8% |
| 2017 | 0.66x | ₩10.94 Billion | ₩7.26 Billion | ▲ +44.7% |
| 2016 | 0.46x | ₩8.79 Billion | ₩4.03 Billion | ▼ -75.9% |
| 2015 | 1.90x | ₩2.43 Billion | ₩4.62 Billion | ▲ +307.6% |
| 2014 | 0.47x | ₩6.18 Billion | ₩2.88 Billion | ▲ +434.8% |
| 2013 | 0.09x | ₩13.57 Billion | ₩1.18 Billion | ▼ -62.9% |
| 2012 | 0.23x | ₩5.77 Billion | ₩1.36 Billion | ▼ -91.3% |
| 2011 | 2.71x | ₩3.43 Billion | ₩9.31 Billion | — |